

# Omeed Moaven

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2662740/publications.pdf>

Version: 2024-02-01

55  
papers

1,533  
citations

331670

21  
h-index

315739

38  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2253  
citing authors

#	ARTICLE	IF	CITATIONS
1	ASO Visual Abstract: Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 2651.	1.5	0
2	Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 2641-2648.	1.5	4
3	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Cancer with Peritoneal Dissemination: 30 Years of Experience at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2022, 234, 546-556.	0.5	5
4	Association of primary tumor laterality with surgical outcomes for colorectal liver metastases: results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC). <i>Hpb</i> , 2022, 24, 1351-1361.	0.3	2
5	ASO Visual Abstract: Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis—A 30-year Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
6	Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 3436-3445.	1.5	11
7	Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC). <i>Journal of Surgical Oncology</i> , 2022, 126, 339-347.	1.7	3
8	Quality analysis of operative reports and referral data for appendiceal neoplasms with peritoneal dissemination. <i>Surgery</i> , 2021, 169, 790-795.	1.9	1
9	Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. <i>JCO Precision Oncology</i> , 2021, 5, 733-743.	3.0	11
10	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. <i>JCO Precision Oncology</i> , 2021, 5, 432-441.	3.0	16
11	Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, 1058-1066.	4.2	6
12	Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2021, , .	1.7	5
13	Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. <i>Annals of Surgical Oncology</i> , 2020, 27, 772-780.	1.5	20
14	ASO Author Reflections: Patient-Reported Outcomes of Mucinous Appendiceal Cancer Improve with Oxaliplatin HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 781-782.	1.5	1
15	ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies. <i>Annals of Surgical Oncology</i> , 2020, 27, 5024-5025.	1.5	2
16	Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis. <i>Journal of Surgical Oncology</i> , 2020, 122, 1604-1611.	1.7	5
17	Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment. <i>Cancers</i> , 2020, 12, 3481.	3.7	9
18	Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 5016-5023.	1.5	10

#	ARTICLE	IF	CITATIONS
19	ASO Author Reflections: Patient-Derived Tumor Organoidsâ€”A Platform for a Precision Approach for Peritoneal Malignancies. <i>Annals of Surgical Oncology</i> , 2020, 27, 4961-4962.	1.5	1
20	Surgical drain placement in distal pancreatectomy is associated with an increased incidence of postoperative pancreatic fistula and higher readmission rates. <i>Journal of Surgical Oncology</i> , 2020, 122, 723-728.	1.7	7
21	Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform. <i>Annals of Surgical Oncology</i> , 2020, 27, 4950-4960.	1.5	36
22	An invited commentary on â€œPostoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysisâ€”(Int J Surg 2019 Sep) Tj ETQq0 0,0 rgBT /Qverlock 10 of Surgery, 2019, 72, 91.	2.7	0
23	Healthcare disparities in outcomes of patients with resectable pancreatic cancer. <i>American Journal of Surgery</i> , 2019, 217, 725-731.	1.8	39
24	Combined Modality Therapy for Management of Esophageal Cancer. <i>Surgical Clinics of North America</i> , 2019, 99, 479-499.	1.5	14
25	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. <i>Cell Metabolism</i> , 2019, 29, 174-182.e5.	16.2	246
26	Disease Biomarkers in Gastrointestinal Malignancies. <i>Disease Markers</i> , 2016, 2016, 1-3.	1.3	2
27	Prevention of antibioticâ€”associated metabolic syndrome in mice by intestinal alkaline phosphatase. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 519-527.	4.4	32
28	Abstract 3781: Combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma. , 2016, , .		3
29	Abstract 4452: Liver selective acetyl-CoA carboxylase inhibition by ND-654 improves survival in cirrhotic rats with hepatocellular carcinoma. , 2015, , .		0
30	Intestinal Alkaline Phosphatase Prevents Antibiotic-Induced Susceptibility to Enteric Pathogens. <i>Annals of Surgery</i> , 2014, 259, 715-722.	4.2	49
31	Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, C826-C838.	3.4	79
32	Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development. <i>Medical Oncology</i> , 2014, 31, 191.	2.5	32
33	Specific MUC1 Splice Variants Are Correlated With Tumor Progression in Esophageal Cancer. <i>World Journal of Surgery</i> , 2014, 38, 2052-2057.	1.6	20
34	Role of hMLH1 and E-Cadherin Promoter Methylation in Gastric Cancer Progression. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 40-47.	1.3	26
35	Two novel mutations in CYP11B1 and modeling the consequent alterations of the translated protein in classic congenital adrenal hyperplasia patients. <i>Endocrine</i> , 2013, 44, 212-219.	2.3	14
36	Intestinal alkaline phosphatase is an endogenous regulator of host microbiota. <i>Journal of the American College of Surgeons</i> , 2013, 217, S14.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G597-G604.	3.4	41
38	Intestinal alkaline phosphatase prevents metabolic syndrome in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7003-7008.	7.1	221
39	Oral supplementation with intestinal alkaline phosphatase: A novel preventive strategy against <i>C. difficile</i> colitis. <i>Journal of the American College of Surgeons</i> , 2012, 215, S48-S49.	0.5	0
40	Expression Analysis Elucidates the Roles of MAML1 and Twist1 in Esophageal Squamous Cell Carcinoma Aggressiveness and Metastasis. <i>Annals of Surgical Oncology</i> , 2012, 19, 743-749.	1.5	47
41	Chilaiditi syndrome: a rare entity with important differential diagnoses. <i>Gastroenterology and Hepatology</i> , 2012, 8, 276-8.	0.1	43
42	High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran. <i>Genetics and Molecular Research</i> , 2011, 10, 3520-3529.	0.2	21
43	Quantitative analysis of TEM-8 and CEA tumor markers indicating free tumor cells in the peripheral blood of colorectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1265-1270.	2.2	24
44	Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy. <i>Cancer Biology and Therapy</i> , 2011, 12, 191-197.	3.4	45
45	Interactions between Glutathione-S-Transferase M1, T1 and P1 polymorphisms and smoking, and increased susceptibility to esophageal squamous cell carcinoma. <i>Cancer Epidemiology</i> , 2010, 34, 285-290.	1.9	26
46	p16 INK4a hypermethylation and p53, p16 and MDM2 protein expression in Esophageal Squamous Cell Carcinoma. <i>BMC Cancer</i> , 2010, 10, 138.	2.6	68
47	Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design. <i>BMC Cancer</i> , 2010, 10, 261.	2.6	20
48	Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. <i>BMC Cancer</i> , 2010, 10, 275.	2.6	18
49	Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 4958.	3.3	42
50	Abstract 4752: Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: Preliminary step for DC vaccine design. , 2010, , .		0
51	Overexpression and Interactions of Interleukin-10, Transforming Growth Factor $\beta^2$ , and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma. <i>World Journal of Surgery</i> , 2009, 33, 1439-45.	1.6	59
52	Clinicopathological significance of E-cadherin, $\beta$ -catenin and p53 expression in gastric adenocarcinoma. <i>Journal of Research in Medical Sciences</i> , 2009, 14, 239-47.	0.9	9
53	M1988 Expression of Cell Adhesion Molecule CD44 in Gastric Adenocarcinoma and Its Correlation with Clinicopathological Characteristics and Survival Time. <i>Gastroenterology</i> , 2008, 134, A-445.	1.3	0
54	p16 promoter hypermethylation: A useful serum marker for early detection of gastric cancer. <i>World Journal of Gastroenterology</i> , 2008, 14, 2055.	3.3	79

#	ARTICLE	IF	CITATIONS
55	Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World Journal of Gastroenterology, 2008, 14, 6376.	3.3	59